David Gómez‐Almaguer

ORCID: 0000-0002-0460-6427 · 3 papers in corpus · active 2011-2017

Study types

  • article 3
article 2017
Danazol as First-Line Therapy for Myelodysplastic Syndrome
·doi:10.1016/j.clml.2017.11.007
article 2016
Danazol As First-Line Therapy for Myelodysplastic Syndromes
·doi:10.1182/blood.v128.22.5528.5528

Abstract Introduction: Myelodysplastic syndromes (MDS) are a heterogeneous group of clonal hematological disorders characterized by ineffective hematopoiesis and variable degrees of peripheral cytopenias. Neither curative nor standard thera…

article 2011
Danazol as first-line therapy for aplastic anemia
·doi:10.1007/s00277-011-1163-x